ixazomib
Sign in to saveIxazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer, in combination with other drugs. It is taken by mouth in the form of capsules.
Chemical data
- Formula
- C14H19BCl2N2O4
- Molecular weight
- 361 g/mol
- IUPAC name
- [(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- +360.081
Show 3 more facts
- P2868
- protease inhibitor
- P2175
- multiple myeloma
- P366
- medication
via Wikidata · CC0
Article
11 sectionsContents
- Medical uses
- Pregnancy and breastfeeding
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- Research
- References
Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer, in combination with other drugs. It is taken by mouth in the form of capsules.
Common side effects include diarrhea, constipation and low platelet count. Like the older bortezomib (which can only be given by injection), it acts as a proteasome inhibitor, has orphan drug status in the US and Europe, and is a boronic acid derivative.